Miraculins Announces Publication of Comprehensive Review Article on Skin Cholesterol and Its Link to Increased Cardiovascular...

Miraculins Inc. (TSX VENTURE:MOM), ("Miraculins" or the "Company") a medical
diagnostic company focused on acquiring, developing and commercializing
diagnostic and risk assessment technologies for unmet clinical needs, announces
today the publication of a review article entitled "The Relationship Between
Skin Cholesterol Testing and Parameters of Cardiovascular Risk: A Systematic
Review" authored by A. Yashar Tashakkor, MD, and G. B. John Mancini, MD, FRCPC
of the Department of Medicine (Division of Cardiology), University of British
Columbia.


The article, currently in press and available online, will be published in an
upcoming issue of the Canadian Journal of Cardiology. In addition to his role as
Professor of Medicine at the University of British Columbia, the senior author,
Dr. G. B. John Mancini, is Director, Cardiovascular Imaging Research Core
Laboratory (CIRCL) at the University of British Columbia, Department of
Medicine, and is Chair of the PreVu(R) Medical Advisory Board. Dr. Mancini has
previously published other peer-reviewed papers on skin cholesterol.


The review article reported on eleven key studies testing patients using a
non-invasive method of skin cholesterol measurement: the PreVu(R) Non-Invasive
Skin Cholesterol Point-of-Care (POC) Test. The results of the systematic review
highlighted the new and independent nature of skin cholesterol measurement data,
which accordingly does not correlate with traditional markers of cardiovascular
disease, such as serum lipid values, but shows a significant relationship with
evidence of underlying atherosclerosis as determined by exercise treadmill
stress testing (for functional cardiovascular disease), coronary angiography
(for coronary artery atherosclerosis), coronary calcium testing (for calcified
coronary plaque), and carotid ultrasound testing both for increased intima-media
thickening and plaque (for carotid artery atherosclerosis). Data extracted from
the unique cohorts were from prospective, observational trials, enlisting a
total of 2,336 participants.


"This timely review of multiple studies on skin cholesterol and its relationship
to cardiovascular risk, highlighting findings from over 2,300 subjects, will
further contribute to the better understanding of the PreVu(R) POC Test and its
practical utility as a new tool to assist in coronary artery disease risk
assessment," said Christopher J. Moreau, President and Chief Executive Officer
of Miraculins Inc. "The PreVu(R) POC Test has been made available on a limited
trial basis over the past year in select Canadian pharmacies as part of a series
of pilot screening programs, and the growing awareness of the value of skin
cholesterol testing will assist us as we transition from piloting to the
national launch of the technology, and its expansion into other markets and
territories as well."


The PreVu(R) POC Test will initially be offered in retail pharmacy settings,
providing a convenient first-step in the screening process to individuals
unaware of their cardiovascular risk status and who have yet to undergo formal
coronary artery disease risk assessment at a physician's office. This systematic
review article provides a foundational scientific reference for all physicians,
including those seeing patients subsequent to their taking a PreVu(R) POC Test.
It will further assist physicians in interpreting the skin cholesterol test
results, which can then be taken into account, along with their own clinical
evaluation of each patient's risk of coronary artery disease, in determining
further diagnostic and patient management options.


About the PreVu(R) Non-Invasive Skin Cholesterol Test

The PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test is a
non-invasive, risk assessment technology designed to measure skin cholesterol -
an emerging biomarker in helping to assess risk of coronary artery disease
("CAD"). The PreVu(R) POC Test is completely painless, non-invasive, involves no
blood draw or needles, and requires no overnight fasting. The test is conducted
on the palm of the hand in less than 5 minutes with results being immediately
available, facilitating point of care consultation and a next steps discussion.
Skin cholesterol is the cholesterol that has been deposited and diffused into
tissue, as opposed to freely circulating in the bloodstream, and the skin
contains approximately 11% of all the cholesterol found in the human body, by
weight. Elevated skin cholesterol has been shown in clinical studies to be
strongly associated with an increased risk of significant CAD as measured by
treadmill stress testing and coronary angiography, as well as measured by
testing for coronary calcium, carotid artery thickening, and carotid artery
plaque. The PreVu(R) POC Test does not diagnose the presence or absence of CAD,
but helps to identify patients who may be at higher, hidden risk for CAD by
measuring their levels of skin cholesterol. The PreVu(R) POC Test is not a
substitute or replacement for blood serum cholesterol testing. For more
information visit www.prevu.com.


About Miraculins Inc.

Miraculins is a medical diagnostic company focused on acquiring, developing and
commercializing non-invasive technologies for unmet clinical needs. A
significant number of promising diagnostic opportunities remain
un-commercialized because of the sizable gap between the discovery stage, when
research institutions are typically involved, and the commercialization stage,
when the larger commercial enterprises become interested. Miraculins has direct
experience in bridging this gap. The Company's PreVu(R) technology is a
revolutionary new coronary artery disease risk assessment technology that
measures cholesterol levels in a patient's skin non-invasively, painlessly and
without the need for fasting. The Company's SCOUT DS(R) system, is the first
non-invasive diabetes screening system designed to provide a highly sensitive
and convenient method for screening for pre-diabetes and type 2 diabetes based
on the presence of diabetes-related biomarkers found in skin. Unlike current
screening methods, a SCOUT DS(R) test requires no blood draw, no fasting, and no
waiting for a lab result. The product has been used and validated in thousands
of patients around the world. The Company's preeclampsia program is partnered
with Alere Inc., one of the world's largest diagnostic companies. For more
information visit www.miraculins.com.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


PreVu(R) and SCOUT DS(R) are registered trademarks of Miraculins Inc. All Rights
Reserved. 2013.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Miraculins Inc.
Christopher Moreau
President & CEO
204-477-7599
204-453-1546 (FAX)
[e-mail]
www.miraculins.com